Welcome to our dedicated page for Anika Therapeutics news (Ticker: ANIK), a resource for investors and traders seeking the latest updates and insights on Anika Therapeutics stock.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global joint preservation company focused on early intervention orthopedics, osteoarthritis (OA) pain management, and regenerative solutions based on hyaluronic acid and implant technologies. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Anika’s clinical programs, product portfolio, and financial performance evolve over time.
News about Anika commonly covers quarterly and annual financial results, including performance in its Commercial Channel and OEM Channel, as well as commentary on operating expenses, cost-saving measures, and capital allocation decisions such as share repurchase programs. Investors can also find updates on governance and compensation topics, including amendments to equity incentive plans and inducement grants made under Nasdaq Listing Rule 5635(c)(4).
A significant portion of Anika’s news flow focuses on clinical and regulatory milestones for its key products. Examples include updates on the U.S. pivotal Phase III FastTRACK study for the Hyalofast cartilage repair scaffold, the filing of the third and final PMA module for Hyalofast with the U.S. Food and Drug Administration, and progress toward a U.S. New Drug Application for Cingal, the company’s non-opioid, single-injection OA pain management product. Releases also describe commercial milestones, such as Cingal surpassing one million injections worldwide and the growth trajectory of the Integrity Implant System.
Corporate and leadership developments are another recurring theme. Anika issues press releases on planned leadership transitions, board changes, and strategic refocusing around its hyaluronic acid portfolio and regenerative solutions. By reviewing the ANIK news stream on this page, readers can monitor how clinical data, regulatory submissions, commercial performance, and governance actions shape the company’s position in osteoarthritis pain management and orthopedic regenerative medicine.
Anika Therapeutics (NASDAQ: ANIK) has completed the divestiture of its Parcus Medical business to Medacta Group SA on March 7, 2025. The transaction was completed with total cash consideration received at closing, subject to customary post-closing adjustments.
This strategic move aligns with Anika's previously announced strategic review, allowing the company to sharpen its focus on its core hyaluronic acid technology and advance its Regenerative Solutions portfolio in early intervention orthopedics.
Both companies have committed to ensuring a smooth transition for employees, distributor agents, surgeon customers, and patients. Goodwin Procter served as legal counsel and Piper Sandler acted as exclusive financial advisor to Anika for the transaction.
Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, has scheduled its fourth quarter and year-end 2024 financial results announcement for Wednesday, March 12, 2025, after market close.
The company will host an investor conference call at 5:00 p.m. ET on the same day to discuss financial results and business highlights. Investors can join via phone using the toll-free domestic number 1-800-717-1738 or international number 1-646-307-1865 with conference ID 89368. A live audio webcast and presentation materials will be available on Anika's website investor relations section.
Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company focusing on early intervention orthopedics, has announced that its President and CEO, Dr. Cheryl Blanchard, will be presenting at the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego.
The presentation is scheduled for Monday, March 10, 2025, at 2:30 PM PT / 5:30 PM ET. In addition to the presentation, Anika's management team will be participating in one-on-one investor meetings throughout the event.
Interested parties can access a live webcast of the presentation on the Events and Webcasts page under the Investors section of Anika's website. The presentation will remain archived on the site for 30 days afterward. Investors seeking to schedule meetings with Anika's senior management during the conference can contact the company's Investor Relations department at investorrelations@anika.com.
Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company specializing in early intervention orthopedics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Dr. Cheryl Blanchard, President and CEO, will deliver a presentation on Thursday, January 16, 2025, at 9:45am PT / 12:45pm ET in San Francisco.
The presentation will be accessible via live webcast on the Events and Webcasts page in the Investors section of Anika's website, remaining available for 30 days afterward. The company's management team will also engage in one-on-one investor meetings throughout the event. Interested parties can arrange meetings through Anika's Investor Relations.
Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company, announced its participation in three major investor conferences this December. The company will attend the 36th Annual Piper Sandler Healthcare Conference in New York on December 3rd, with a presentation at 10:30am ET. They will also participate in the Sidoti Small-Cap Virtual Conference on December 5th with a presentation at 10:45am ET, and the Benchmark Company 13th Annual Discovery One-on-One Investor Conference in New York on December 11th. Senior management, including CEO Dr. Cheryl Blanchard and CFO Steve Griffin, will conduct one-on-one investor meetings throughout these events.
Arthrosurface, a leading provider of joint restoration and preservation solutions, has been acquired from Anika Therapeutics (NASDAQ: ANIK) by Primo Medical Group executives and former Arthrosurface leaders. The company specializes in minimally invasive techniques with a portfolio of over 150 different surface implant curvatures for knee, shoulder, wrist, and toe treatments. Under new ownership through Phoenix Brio, Arthrosurface will maintain its operations in West Bridgewater, Massachusetts, with no expected disruption to product access or customer service.
Anika Therapeutics (ANIK) reported Q3 2024 revenue of $38.8 million, down 7% year-over-year. The company announced the sale of Arthrosurface and planned divestiture of Parcus Medical to focus on OA Pain Management and Regenerative Solutions. Key highlights: U.S. OA Pain Management revenue declined 5%, while Regenerative Solutions grew 17%, led by the Integrity Implant System's 40%+ sequential growth. Net loss was $29.9 million or $2.03 per share. The company will now categorize revenue into OEM Channel and Commercial Channel, with Commercial Channel on track for ~17% CAGR since 2021. First module of Hyalofast PMA was filed in October, targeting U.S. launch by 2026.
Anika Therapeutics (NASDAQ: ANIK) announced strategic changes including the sale of Arthrosurface and plans to divest Parcus Medical. The company sold Arthrosurface to Phoenix Brio for $10 million, comprising a $7 million ten-year non-interest bearing note and up to $3 million in performance-based consideration. The company will now focus on its core hyaluronic acid technology and Regenerative Solutions portfolio, targeting a $4 billion total addressable market. Support services will continue through early 2025 to ensure product continuity. The Parcus Medical divestiture process is ongoing, with the business operating in the $3 billion global sports medicine market.
Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company specializing in early intervention orthopedics, has announced the date for its Third Quarter 2024 Results Conference Call. The company will release its financial results before the market opens on Thursday, October 31, 2024. This will be followed by a conference call at 8:30 a.m. ET to discuss the results and business highlights.
Interested parties can access the conference call by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and using the conference ID number 31842. Additionally, a live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website at www.anika.com. The call will be archived and accessible on the same website shortly after its conclusion.
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, has announced the granting of non-statutory stock options to a newly hired non-executive employee. The grant, made on October 1, 2024, covers 6,350 shares of common stock with a per share exercise price of $24.27, matching the closing price on the Nasdaq Global Select Market on the grant date.
The options were granted under the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, and approved by the compensation committee of the board of directors. In accordance with Nasdaq Listing Rule 5635(c)(4), the grant serves as a material inducement for the employee's acceptance of employment. The vesting schedule includes one-third of the shares vesting on each of the first three anniversaries of the grant date, contingent on continuous service. The options will expire on the tenth anniversary of the grant date unless terminated earlier.